id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-341819-emjg3dsw	Kouznetsova, Valentina L.	Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs	2020-09-18		.txt	text/plain	3312	178	54	Using the crystal structure of SARS-CoV-2 papain-like protease (PL(pro)) as a template, we developed a pharmacophore model of functional centers of the PL(pro) inhibitor-binding pocket. In a previous report, we (Kouznetsova, Huang & Tsigelny, 2020 ) and others (Kandeel & Al-Nazawi, 2020; Arya et al., 2020; Plewczynski et al., 2007; Ton et al., 2020) have used molecular modeling studies to identify FDA-approved drugs and other compounds (Arya et al., 2020; Ton et al., 2020; Alamri, Tahir ul Qamar & Alqahtani, 2020) that are predicted to bind to 3CL pro . Based on the crystal structure of SARS-CoV-2 PL pro (PDB ID: 6W9C), we developed two pharmacophore models of the binding pocket of this protein. We developed a pharmacophore model of the binding pocket site S3/S4 of COVID-19 PL pro then conducted multi-conformational docking of these drug compounds to this site for ranging the potential inhibitors selected by pharmacophore-based search. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs	./cache/cord-341819-emjg3dsw.txt	./txt/cord-341819-emjg3dsw.txt